Kyle O'Neil

Kyle M. O’Neil is a consultant at Back Bay Life Science Advisors, where he has completed over 30 projects across both therapeutics and medical devices. He has worked extensively across novel therapeutics (e.g. cell therapies, CRISPR, gene therapies, and RNA modalities), with a particular focus on rare disease, neurology, and oncology.

Previously, Mr. O’Neil worked at GlaxoSmithKline, where he led a strategic assessment of clinical trial diversity for the US Clinical Operations team. Prior to GlaxoSmithKline, Mr. O’Neil also spent time at L’Oréal where he worked in Research and Innovation.

Mr. O’Neil holds both a B.S.E. and M.S.E. in Bioengineering from the University of Pennsylvania, where he was also a Fellow at the Penn Center for Innovation, a role in which he managed the technical, commercial, and legal aspects of technology disclosures for patentability and business decisions.